Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.

Patients with NE differentiation had different clinical characteristics and a better prognosis than patients with pure NEPC. In addition, low-serum PSA levels were associated with a poorer prognosis in patients with either NEPC or NE differentiation.